研究者業績

蟹江 匡治

kanie tadaharu

基本情報

所属
藤田保健衛生大学 医学部 医学科 血液内科学 講師
学位
博士(医学)

J-GLOBAL ID
201501004387124081
researchmap会員ID
7000012777

MISC

 4
  • Akinao Okamoto, Masamitsu Yanada, Yoko Inaguma, Masutaka Tokuda, Satoko Morishima, Tadaharu Kanie, Yukiya Yamamoto, Motohiro Tsuzuki, Yoshiki Akatsuka, Shuichi Mizuta, Masataka Okamoto, Nobuhiko Emi
    Hematology 18(2) 74-80 2013年3月  査読有り
    The beneficial effect of rituximab for first-line treatment of diffuse large B-cell lymphoma (DLBCL) has been demonstrated by several randomized controlled trials. To clarify whether results for selected patient populations also apply to unselected patients, we analyzed long-term outcomes for all the 277 consecutive adults diagnosed with de novo DLBCL in a single center between 1998 and 2008. The study population included 147 and 130 patients diagnosed before (Cohort A) and after the advent of rituximab (Cohort B). Progression-free survival (PFS) was significantly better for Cohort B than for Cohort A (P = 0.005). For patients age 60 or younger, PFS did not differ significantly between Cohort A and Cohort B (P = 0.329), but for patients over 60, Cohort B showed superior PFS (P = 0.002). Patients with high or high-intermediate risk according to the International Prognostic Index score showed less improvement in PFS than did those with low or low-intermediate risk primarily because of still unfavorable outcomes of patients with poor performance status. These results indicate that the advent of rituximab has significantly improved outcome for unselected patients with DLBCL, and that improvement was greater for older patients. Further investigations are warranted in the hope of improving outcomes for younger patients with DLBCL. © W. S. Maney & Son Ltd 2013.
  • Akihiro Abe, Akira Katsumi, Miki Kobayashi, Akinao Okamoto, Masutaka Tokuda, Tadaharu Kanie, Yukiya Yamamoto, Tomoki Naoe, Nobuhiko Emi
    Cancer Genetics 205(11) 608-611 2012年11月  査読有り
    The RUNX1 locus, which encodes a transcription factor that is essential for normal hematopoiesis, is a frequent location of chromosomal rearrangements in human hematological malignancies. We report the case of a 78-year-old man with acute myeloid leukemia (AML), M1 subtype (French-American-British classification), with a t(11;21)(p14;q22). Fluorescence in situ hybridization showed a split signal for RUNX1, which indicated that RUNX1 was involved in this translocation. Using 3'-rapid amplification of cDNA ends and reverse transcription-polymerase chain reaction analyses, we found that RUNX1 was fused to C11orf41 on 11p14 and detected two in-frame C11orf41-RUNX1 fusion transcripts. One was a fusion between exon 5 of RUNX1 and exon 13 of C11orf41, and the other was between exon 6 of RUNX1 and exon 13 of C11orf41. This suggested that the RUNX1 breakpoint was in intron 6 and had generated alternative fusion splice variants. A reciprocal C11orf41-RUNX1 fusion was not detected. Thus, we identified C11orf41 as a novel fusion partner of RUNX1 in AML. © 2012 Elsevier Inc.
  • Akinao Okamoto, Akihiro Abe, Masataka Okamoto, Tsukane Kobayashi, Tomohiko Terazawa, Yoko Inaguma, Masutaka Tokuda, Masamitsu Yanada, Satoko Morishima, Tadaharu Kanie, Yukiya Yamamoto, Motohiro Tsuzuki, Yoshiki Akatsuka, Shuichi Mizuta, Tetsushi Yoshikawa, Nobuhiko Emi
    International Journal of Hematology 96(4) 516-520 2012年10月  査読有り
    Severe disseminated varicella zoster virus (VZV) infection rarely occurs in patients who are not recipients of hematopoietic stem cell transplantation. This report concerns severe disseminated VZV infection in a diffuse large B cell lymphoma (DLBCL) patient treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). The patient was an 82-year-old male with DLBCL who had a history of type II diabetes mellitus. He incurred VZV infection with severe hepatitis and disseminated intravascular coagulopathy after three courses of R-CHOP. When the VZV infection occurred, anti-VZV IgG was not detected and lymphopenia was observed. We initiated treatment with acyclovir, immunoglobulin, and thrombomodulin alpha, and rescued this patient. We suggest that the use of chemotherapy for immune-suppressed elderly lymphoma patients may involve the risk of severe VZV infection. © The Japanese Society of Hematology 2012.
  • Y. Inamoto, M. Murata, A. Katsumi, Y. Kuwatsuka, A. Tsujimura, Y. Ishikawa, K. Sugimoto, M. Onizuka, S. Terakura, T. Nishida, T. Kanie, H. Taji, H. Iida, R. Suzuki, A. Abe, H. Kiyoi, T. Matsushita, K. Miyamura, Y. Kodera, T. Naoe
    BONE MARROW TRANSPLANTATION 45(2) 363-369 2010年2月  査読有り
    The interactions between chemokines and their receptors may have an important role in initiating GVHD after allogeneic hematopoietic SCT (allo-HSCT). CCL25 and CCR9 are unique because they are exclusively expressed in epithelial cells and in Peyer's patches of the small intestine. We focused on rs12721497 (G926A), one of the non-synonymous single nucleotide polymorphisms (SNPs) in the CCR9 gene, and analyzed the SNP of donors in 167 consecutive patients who received allo-HSCT from an HLA-identical sibling donor. Genotypes were tested for associations with acute and chronic GVHD in each organ and transplant outcome. Multivariate analyses showed that the genotype 926AG was significantly associated with the incidence of acute stage >= 2 skin GVHD (hazard ratio: 3.2; 95% confidence interval (95% CI): 1.1-9.1; P = 0.032) and chronic skin GVHD (hazard ratio: 4.1; 95% CI: 1.1-15; P = 0.036), but not with GVHD in other organs or with relapse, non-relapse mortality or OS. To clarify the functional differences between genotypes, each SNP in retroviral vectors was transfected into Jurkat cells. In chemotaxis assays, the 926G transfectant showed greater response to CCL25 than the 926A transfectant. In conclusion, more active homing of CCR9-926AG T cells to Peyer's patches may produce changes in Ag presentation and result in increased incidence of skin GVHD. Bone Marrow Transplantation (2010) 45, 363-369; doi:10.1038/bmt.2009.131; published online 15 June 2009

講演・口頭発表等

 11

教育内容・方法の工夫(授業評価等を含む)

 1
  • 件名
    血液内科の講義、学生指導、試験問題の作成
    開始年月日
    2010
    終了年月日
    2013
    概要
    M3,M4の学生に対し、血液内科分野の講義を行う。M5のポリクリ学生に対し、個別指導や少人数講義、症例発表の指導を行う。血液内科の試験問題の作成や試験監督、OSCEを担当する。

作成した教科書、教材、参考書

 1
  • 件名
    講義用のPPT作成
    開始年月日
    2010
    終了年月日
    2013
    概要
    医学部講義用にわかりやすいPPTを作成している。

その他教育活動上特記すべき事項

 1
  • 件名
    PBL、医学教育ワークショップ
    開始年月日
    2010
    終了年月日
    2013
    概要
    M3およびM4に対し、PBLの指導を行う。第38回医学教育ワークショップに参加している。